RT Journal Article
SR Electronic
T1 Replication and cross-validation of T2D subtypes based on clinical variables: an IMI-RHAPSODY study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.21.20248628
DO 10.1101/2020.12.21.20248628
A1 Slieker, Roderick C
A1 Donnelly, Louise A
A1 Fitipaldi, Hugo
A1 Bouland, Gerard A
A1 Giordano, Giuseppe N.
A1 Åkerlund, Mikael
A1 Gerl, Mathias J.
A1 Ahlqvist, Emma
A1 Ali, Ashfaq
A1 Dragan, Iulian
A1 Festa, Andreas
A1 Hansen, Michael K.
A1 Aly, Dina Mansour
A1 Kim, Min
A1 Kuznetsov, Dmitry
A1 Mehl, Florence
A1 Klose, Christian
A1 Simons, Kai
A1 Pavo, Imre
A1 Pullen, Timothy J.
A1 Suvitaival, Tommi
A1 Wretlind, Asger
A1 Rossing, Peter
A1 Lyssenko, Valeriya
A1 Quigley, Cristina Legido
A1 Groop, Leif
A1 Thorens, Bernard
A1 Franks, Paul W
A1 Ibberson, Mark
A1 Rutter, Guy A
A1 Beulens, Joline WJ
A1 ’t Hart, Leen M
A1 Pearson, Ewan R
YR 2020
UL http://medrxiv.org/content/early/2020/12/22/2020.12.21.20248628.abstract
AB Aims/hypothesis Five clusters based on clinical characteristics have been suggested as diabetes subtypes: one autoimmune and four subtypes of type 2 diabetes (T2D). In the current study we replicate and cross-validate these T2D clusters in three large cohorts using readily measured variables in the clinic.Methods In this cross-sectional study, 15,940 individuals were clustered based on age, BMI, HbA1c, random or fasting C-peptide and HDL in three independent cohorts. Clusters were cross-validated against the original clusters based on HOMA measures. In addition, between cohorts, clusters were cross-validated by re-assigning people based on each cohort’s cluster centres.Results Five distinct T2D clusters were identified and mapped back to the original four ANDIS clusters. Using C-peptide and HDL instead of HOMA-B and HOMA-S three of the clusters mapped with high sensitivity (80.6 – 90.7%) to the previously identified Severe Insulin Deficient (SIDD), Severe insulin resistant (SIRD) and Obese (MOD) clusters. The previously described ANDIS MARD cluster could be mapped to the two milder groups in our study – one characterised by high HDL, and the other having not any extreme characteristic (MDH cluster). When these two milder groups were combined they mapped well to the previously labelled MARD cluster (sensitivity 79.4%). In the cross-validation between cohorts, particularly the SIDD and MDH cluster cross-validated well with sensitivities ranging from 73.3% to 97.1%. SIRD and MD showed a lower sensitivity ranging from 36.1% to 92.3% where individuals shifted from SIRD to MD and vice versa.Conclusions/interpretation Clusters based on C-peptide instead of HOMA measures result in clusters that resemble those based on HOMA measures, especially for SIDD, SIRD and MOD. By adding HDL, the MARD cluster based upon HOMA measures resulted in the current clustering in two clusters with one cluster having high HDL levels. Cross-validation between cohorts showed generally a good resemblance between cohorts. Together, our results show that the clustering based on clinical variables readily measured in the clinic (age, HbA1c, HDL, BMI and C-peptide) results in informative clusters that are representative of the original ANDIS clusters and stable across cohorts.Competing Interest StatementKS is CEO of Lipotype GmbH. KS and CK are shareholders of Lipotype GmbH. MJG is employee of Lipotype GmbH. GAR has received grant funding and consultancy fees from Sun Pharmaceuticals and Les Laboratoires Servier. MKH is an employee of Janssen Research & Development, LLC. AF and IP are employees of Eli Lilly Regional Operations GmbH.Funding StatementInnovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115881 (RHAPSODY) Swiss State Secretariat for Education, Research and Innovation (SERI) under contract number 16.0097−2Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study has been approved by the Ethical Review Committee of the VU University Medical Center, Amsterdam.The GoDARTS study was approved by the Tayside Medical Ethics Committee. Informed consent was obtained from all participants.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesClinical data will not be deposited for this study.